Skip to main
ENGN

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 14%
Buy 71%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

enGene Holdings Inc. is demonstrating a positive outlook due to significant advancements in its gene therapy offerings, particularly with the RMAT designation for detalimogene, which positions the therapy to capture considerable market share in community practice settings. The company’s clinical data indicates an improvement in complete response rates that align with best-in-class therapies while maintaining a superior overall profile due to the non-viral delivery method, which may enhance adoption across various treatment settings. Additionally, the increase in research and development expenses reflects a commitment to advancing pivotal studies like the LEGEND study, contributing to an optimistic assessment of the company's growth potential and an upward adjustment in valuation metrics.

Bears say

enGene Holdings Inc's stock faces a negative outlook due to disappointing performance of its product Detalimogene in the ongoing LEGEND trial, which has been marred by unexpected safety issues and changing regulatory requirements for approvals. Additionally, the emergence of unforeseen competition and a higher-than-expected capital requirement raise concerns about the company's ability to secure funding without significant equity dilution, potentially impacting share value. The critical complete response rates observed in preliminary cohorts are currently less competitive compared to peer products, emphasizing the company's vulnerability in a highly competitive biotechnology landscape.

ENGN has been analyzed by 7 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 71% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 7 analysts, ENGN has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.